Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial

917 patients with type 2 diabetes were randomized to receive tirzepatide or insulin glargine.

• Tirzepatide doses of 5 mg, 10 mg, and 15 mg achieved a reduction in hemoglobin A1c (HbA1c) of -2.24%, -2.44%, and -2.49%, respectively, compared to -0.95% with insulin glargine.
• The treatment difference in HbA1c reduction between tirzepatide and insulin glargine ranged from -1.29% to -1.54% (all P < 0.001).
• A higher proportion of patients receiving tirzepatide achieved HbA1c levels below 7.0% at week 40: 75.4% for 5 mg, 86.0% for 10 mg, and 84.4% for 15 mg, versus 23.7% for insulin glargine (all P < 0.001).
• All doses of tirzepatide were associated with significant body weight reduction: -5.0 kg for 5 mg, -7.0 kg for 10 mg, and -7.2 kg for 15 mg, while insulin glargine was associated with a weight increase of 1.5 kg (all P < 0.001).
• The most common side effects of tirzepatide included mild to moderate decreased appetite, diarrhea, and nausea, with no reports of severe hypoglycemia.

AI simplified